Coya Therapeutics Inc. (COYA)
NASDAQ (CM) NASDAQ (CM) Primary 
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?
Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?
Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates
Coya Therapeutics, Inc. (COYA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.19 per share a year ago.
Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?
Coya Therapeutics, Inc. (COYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year?
Here is how Coya Therapeutics, Inc. (COYA) and Doximity (DOCS) have performed compared to their sector so far this year.
Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release
Positive interim data by Coya Therapeutics released from 5 patients in an investigator-initiated proof-of-concept study using COYA-302 for the treatment of patients with FTD. An IND filing and phase 2b initiation of COYA-302 to treat FTD patients expected in the 2nd half of 2025. It is said that the 7 major markets for the Frontotemporal Dementia market is expected to reach $596.3 million by 2034.
Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High?
The consensus price target hints at a 144.7% upside potential for Coya Therapeutics, Inc. (COYA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock
Coya Therapeutics, Inc. (COYA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet
The consensus price target hints at a 149.6% upside potential for Coya Therapeutics, Inc. (COYA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD
Coya Therapeutics, Inc. has Treg therapies for neurodegenerative and autoimmune diseases, targeting ALS, FTD, AD, and PD. However, their lead candidate is now clearly COYA 302. This drug basically combines low-dose IL-2 and CTLA4-Ig, and it's now progressing toward Phase 2 trials for ALS and FTD. COYA 301 was intended for AD, but its mixed Phase 2 results may be why COYA is now pivoting toward COYA 302.
Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch
Potential initiation of phase 2b study using COYA-302 for the treatment of patients with Amyotrophic Lateral Sclerosis, expected in 2025 barring successful IND clearance by the FDA. Biomarker data from proof-of-concept study using COYA-302 for the treatment of patients with Amyotrophic Lateral Sclerosis, expected in Q2 of 2025. The global Amyotrophic Lateral Sclerosis market is expected to reach $1.33 billion by 2033.
Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing
On Thursday, Coya Therapeutics, Inc. COYA announced blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients with Alzheimer's disease (AD).
